Corcept's ROSELLA Phase 3 posts results for relacorilant plus nab-paclitaxel in ovarian cancer
Results were first posted for the Phase 3 ROSELLA trial testing relacorilant with nab-paclitaxel against nab-paclitaxel alone in platinum-resistant ovarian cancer.
Corcept Therapeutics' single active trial this week is the Phase 3 ROSELLA study, which reported new results data.
- Relacorilant (also known as Lifyorli) combined with nab-paclitaxel is being tested in a Phase 3 trial against nab-paclitaxel alone in patients with advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer1. The study's status is active, not recruiting, with results first posted on 2026-09-251, and it enrolled 381 participants1. The trial measures progression-free survival by blinded independent central review and overall survival as dual primary endpoints1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.